Mr. Xin Huang is Managing Partner of Co-win Ventures. He started Co-win Ventures' healthcare practice and has since led the investment. He has over 20 years of experience in clinical medicine, translational research, healthcare management consulting and venture capital investment and his profession in venture capital started in 2010.
      Mr. Huang has led and participated in deals such as CytekBio (CTKB.US), Connect Pharm (CNTB.US) , Thrive (acquired by EXAS.US), Immorna, Aucta Pharm, D1 Med Technology, Sniper, Celsius, CytoChip, Complete Omics, Leads Biolabs, CF PharmTech, Mab Venture, 3DMed, PGDx etc.
      Mr. Huang has been named to the China TOP 30 Angel Investors by Entrepreneurship Foundation & CV INFO and the TOP 50 Most Influential Investors by CHC & Citic Securities for 2021.
      Prior to joining Co-win Ventures, Mr. Huang served as Management Consultant of BCG and Senior Investment Manager of Omaha Capital.
      Mr. Huang holds an M.D. from Peking Union Medical College and a Ph.D. from Johns Hopkins University. He was ranked No.1 in the National College Entrance Exam in China in 1995.